You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

AbstractFullPdf
Mar 2022661673249
Apr 2022316326123
May 202224324784
Jun 2022229242104
Jul 202220421060
Aug 202220721340
Sep 202220821744
Oct 202219620357
Nov 202214114330
Dec 202211211220
Jan 202312312547
Feb 202314014038
Mar 202311211374
Apr 2023919442
May 202311211236
Jun 2023868629
Jul 2023838535
Aug 202310210236
Sep 2023848424
Oct 2023818134
Nov 2023818130
Dec 2023636428
Jan 2024454522
Feb 2024575723
Mar 202410711033
Total388439651342